Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea

As targeted therapy becomes increasingly important, diagnostic techniques for identifying targeted biomarkers have also become an emerging issue. The study aims to evaluate the cost-effectiveness of treating patients as guided by epidermal growth factor receptor (EGFR) mutation status compared with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2016-08, Vol.11 (8), p.e0160155-e0160155
Hauptverfasser:	Lim, Eun-A, Lee, Haeyoung, Bae, Eunmi, Lim, Jaeok, Shin, Young Kee, Choi, Sang-Eun
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - economics Adenocarcinoma - pathology Adenocarcinoma of Lung Aged Analysis Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Asian people Biological markers Biomarkers Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - economics Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Chemotherapy Clinical medicine Comparative analysis Computer simulation Cost analysis Cost-Benefit Analysis Decision Trees Diagnosis Diagnostic systems Diagnostic tests Economic aspects Epidermal growth factor Epidermal growth factor receptors Epidermal growth factors ErbB Receptors - genetics Erlotinib Hydrochloride - economics Erlotinib Hydrochloride - therapeutic use Female Gene Expression Genetic aspects Health care Health Care Costs Health care policy Histology Humans Laboratories Lung cancer Lung diseases Lung Neoplasms - drug therapy Lung Neoplasms - economics Lung Neoplasms - pathology Male Markov Chains Markov processes Medical diagnosis Medicine and Health Sciences Middle Aged Molecular Targeted Therapy Mutation Neoplasm Staging Non-small cell lung cancer Non-small cell lung carcinoma Patients Pharmacy Physiological aspects Population studies Precision Medicine Protein Kinase Inhibitors - economics Protein Kinase Inhibitors - therapeutic use Quality-Adjusted Life Years Republic of Korea Risk factors Sensitivity analysis Social Sciences Strategy Studies Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!